Sparks commentary - IRLAB Therapeutics

Healthcare

Sparks - IRLAB Therapeutics

More on this equity
IRLAB (OMX: IRLAB-A) publishes preclinical mesdopetam data in journal
Published by Arron Aatkar, PhD

IRLAB Therapeutics has announced the publication of preclinical data on mesdopetam in the prestigious peer-reviewed journal, European Journal of Neuroscience. The research provided insights into the mechanisms behind the antidyskinetic properties of mesdopetam, as well as its potential to address psychosis in Parkinson’s disease patients.

Mesdopetam is IRLAB’s lead clinical asset. Provided the company secures a suitable partner, a Phase III programme in levodopa-induced dyskinesias could be launched within 2025.

Latest

Healthcare | Comment

Cantargia (OMX: CANTA) enrols first patient in leukaemia study

Healthcare | Comment

Cantargia (OMX: CANTA) breast cancer study fully recruited

Industrials | Comment

NWF (LON: NWF) acquires Northern Energy Oil

Healthcare | Comment

Cantargia (OMX: CANTA) reports positive CAN10 update

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free